Review of osteoporosis pharmacotherapy for geriatric patients

Gates, Brian J.; Sonnett, Travis E.; DuVall, Cristina A.K.; Dobbins, Erin K.

doi:10.1016/j.amjopharm.2009.12.004

Cited by 43 publications

(25 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current pharmacotherapy for managing osteoporosis in geriatric patients includes various options such as bisphosphonate, calcitonin, raloxifene, vitamin D, and ipriflavone [15]. Therefore, it is important to compare the relative safety and associated risk of atrial fibrillation among these treatments including bisphosphonate.…”

Section: Introductionmentioning

confidence: 99%

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis

Rhee

Lee

et al. 2011

Osteoporos Int

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis

Rhee

Lee

et al. 2011

Osteoporos Int

View full text Add to dashboard Cite

show abstract

“…Bisphosphonates are the antiresorptive agents which are most commonly used to treat OP and reduce the risk of hip fracture in the elderly patients mostly. Even after bisphosphonates are discontinued, their positive effects on bone are maintained and they are the best agents to prefer in senile and male OP [5,12,14,15]. Based on these, we planned this study to compare the effects and possible side effects on bone mineral density of two bisphosphonate medications used to treat osteoporosis.…”

Section: Discussionmentioning

confidence: 99%

Comparative evaluation of clinical effectivity and side effects of two different parenteral agents used in the treatment of osteoporosis

Aslan¹,

Özmeriç²,

Bilal³

et al. 2014

J Rheumatol Orthop

View full text Add to dashboard Cite

Objective: In this study, we aimed to make a comparative analysis of short term clinical effectivity and side effects of intravenous zoledronate administration as single dose yearly and intravenous ibandronate administration as four doses per year. Methods: The patients whom were included in our study had osteoporosis according to WHO criteria and were treated with either parenteral zoledronate or ibandronate. 43 patients were treated with single dose of 5mg intravenous zolendronat which was applied once in a year; whereas in 39 patients were treated with 3 mg intravenous ibandronate which was applied four times in a year in three months intervals. Biochemical tests were performed in all patients before intravenous drug infusion. Side effects during drug administration and also in the first three months of the treatment were noted for all patients. Clinical effectivity was analyzed according to changes in bone mineral density (BMD) at the end of two year after treatment. Results: Eighty-two patients who were followed-up and evaluated for the effectivity and side effects of the treatment were included in our study. The compliance of patients were 100% in both groups. Mean age was 75.23±6.9 years and mean body mass index (BMI) was 26.94±7.2. In zoledronate group in which there were 23 females and 20 males. Mean age was 73.64±8.7 years and mean BMI was 27.34±4.4. In ibandronate group in which there were 39 females. There were no statistically significant differences between the groups in terms of gender (p=0.000) Mean age, BMI and rate of diagnosed side effects were not statistically significant in between the groups. According to a one-year follow-up in both groups comparison with before application had a statistically significant increase in BMD (p<0.01). However, a one-year follow-up between the two groups in terms of mean values of bone mineral density did not differ significantly (p>0.05). Conclusion: Choice of medical treatment is decided according to bone mineral density and personal risk factors in osteoporosis. Parenteral agents in the treatment of osteoporosis may be the preferred choice for the patients with comorbid diseases, using multiple drug therapies, or having trouble in using oral drug therapy. However, it should always be kept in mind that drug related side effects may be seen more commonly with parenteral agents. Clinicians should be aware of the probable side effects during and after application.

show abstract

“…Günlük ve aylık oral ibandronatın kırıklar üzerindeki etkinliğini araştıran "The iB Bandronate O Osteoporosis vertebral fracture trial in N North America and E Europe (BONE)" çalışması; vertebra kırıklarını %50, nonvertebral kırık insidansını %69 oranında azalttığını göstermiştir. 34 Bazı meta-analizlerde her iki-üç ayda bir 2 mg ya da 3 mg kullanımın vertebral kı-rıkları azalttığı saptanmıştır. 30,35 Z Zo ol le ed dr ro on ni ik k a as si it t: : Zoledronik asit postmenopozal osteoporoz tedavisinde onay almıştır.…”

Section: Farmakoloji̇k Tedavi̇unclassified

“…Senil osteoporozda ilk seçilecek ajan değildir. 40,41 c c) ) K Ka al ls si it to on ni in n: : Kalsitonin, tiroid bezi tarafından üretilen polipeptid bir hormondur. FDA, Paget hastalığı, hiperkalsemi ve beş yıldan uzun süredir menopozda olan osteoporozlu kadınların tedavisinde kullanımını onaylamıştır.…”

Section: B B) ) Sunclassified

Osteoporosis: Screening, Prevention and Treatment: Review

Cengiz¹,

Yürüyen²

2016

Turkiye Klinikleri J Intern Med

View full text Add to dashboard Cite

Review of osteoporosis pharmacotherapy for geriatric patients

Cited by 43 publications

References 115 publications

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis

Comparative evaluation of clinical effectivity and side effects of two different parenteral agents used in the treatment of osteoporosis

Osteoporosis: Screening, Prevention and Treatment: Review

Contact Info

Product

Resources

About